Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Lyra Therapeutics, Inc. reported revenue of $0M, down 74.1% year over year. Operating margin was -7794.5% and net margin -7266.1%, on a free-cash-flow margin of -7280.2% with capital expenditure at 29.1% of revenue. Every figure is computed directly from LYRA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $0M | -7794.5% | -7266.1% |
| FY2024 | $2M | -6280.8% | -6090.9% |
| FY2023 | $2M | -4308.1% | -4023.1% |
| FY2022 | $1M | -4131.0% | -4055.6% |
| FY2021 | $0M | -15303.5% | -15267.7% |
How does LYRA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.